ArticleNPJ breast cancer2021
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
Article in NPJ breast cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- "For and against" factors influencing participation in personalized breast cancer screening programs: a qualitative systematic review until March 2022.Archives of public health = Archives belges de sante publique · 2024Pooled it
- Trial
- Supporting informed decisions about breast cancer screening in communities with known environmental contamination: a pre-post study.Cancer causes & control : CCC · 2025Trial
- WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.NPJ breast cancer · 2026Article
- Article
- WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and Design.Research square · 2025Article
- Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.NPJ breast cancer · 2024Article
- Twin studies as an innovative approach to address research questions in cancer care within primary care settings.Family medicine and community health · 2024Article
- The role of polygenic risk scores in breast cancer risk perception and decision-making.Journal of community genetics · 2023Article
- Article
- Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).British journal of cancer · 2023Article
- Perceptions and Usability of PREVENTION: A Breast Cancer Risk Assessment e-Platform.Journal of personalized medicine · 2023Article
- Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.Research square · 2023Article
- Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- BREAst screening Tailored for HEr (BREATHE)-A study protocol on personalised risk-based breast cancer screening programme.PloS one · 2022Article
- Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.NPJ breast cancer · 2021Article
- Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.NPJ breast cancer · 2021Article
- A Scoping Review of Personalized, Interactive, Web-Based Clinical Decision Tools Available for Breast Cancer Prevention and Screening in the United States.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Breast cancer risk reduction has been validated by large-scale clinical trials, but uptake remains low. A risk communication tool could provide personalized risk-reduction information for high-risk women. A low-literacy-friendly, visual, and personalized tool was designed as part of the Women Informed to Screen Depending On Measures of risk (WISDOM) study. The tool integrates genetic, polygenic, and lifestyle factors, and quantifies the risk-reduction from undertaking medication and lifestyle interventions. The development and design process utilized feedback from clinicians, decision-making scientists, software engineers, and patient advocates. We piloted the tool with 17 study participants, collecting quantitative and qualitative feedback. Overall, participants felt they better understood their personalized breast cancer risk, were motivated to reduce their risk, and considered lifestyle interventions. The tool will be used to evaluate whether risk-based screening leads to more informed decisions and higher uptake of risk-reduction interventions among those most likely to benefit.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.